GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Rhythm Pharmaceuticals
The shares of Rhythm Pharmaceuticals, a company treating rare genetic forms of obesity, are extremely volatile. Their price depends on the commercial success of its drugs and the results of clinical trials. The chart is a classic biotech story, where science directly drives the stock.
Share prices of companies in the market segment - Pharma metabolism
Rhythm Pharmaceuticals operates in the biotechnology segment, specializing in the treatment of rare genetic forms of obesity. We classify it in the Metabolic Pharmaceuticals sector. The chart below reflects the dynamics of this entire innovative, yet risky, segment.
Broad Market Index - GURU.Markets
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases associated with obesity. Its niche expertise earns it a spot in the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
RYTM - Daily change in the company's share price Rhythm Pharmaceuticals
Change_Co for Rhythm Pharmaceuticals (RYTM), a biotech company focused on rare genetic diseases, reflects its sensitivity to clinical trials, FDA approvals, and product commercialization. RYTM's volatility is high, typical for biopharma. This metric is essential for formulaic modeling of risks and potential in niche biotech.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Rhythm Pharmaceuticals, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with RYTM's performance, which hinges on the success of its drugs for treating rare genetic forms of obesity, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Rhythm Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic diseases that cause obesity. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Rhythm's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Rhythm Pharmaceuticals
Rhythm is a biotech company specializing in the treatment of rare genetic diseases that cause obesity. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on treating rare genetic diseases that cause obesity. Its success depends on the commercialization of its first drug. The graph reflects the high risks and potential for breakthroughs in this complex and important area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rhythm Pharmaceuticals is a biotech company whose fate depends entirely on the success of its drugs for rare diseases. Its stock price is unrelated to economic cycles. The company's chart is a story of scientific breakthroughs, clinical trials, and regulatory decisions, not macroeconomic news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, a biotech company focused on treating rare genetic diseases that cause obesity. The monthly fluctuations on the chart reflect the clinical data and commercial success of its ultra-niche drugs.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
This chart reflects the dynamics of the biotech sector. For Rhythm, with its focus on treating rare genetic forms of obesity, it's the backdrop. Its movements show how the company, with an approved drug, is commercializing its therapy and expanding its use.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rhythm Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare genetic forms of obesity. This is a highly specialized area of medicine. The chart below shows general market trends. Does Rhythm live in a world of its own, where research results rule the roost rather than market sentiment?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, a biopharmaceutical company focused on rare genetic obesity diseases, is experiencing high volatility. Its weekly stock price is reflecting a sharp reaction to clinical trial results and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Rhythm Pharmaceuticals operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether RYTM is moving with the industry or whether its successes in treating rare diseases are creating its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Rhythm Pharmaceuticals, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how RYTM shares can live their own life, separate from the broader market, moving on their own news.
Market capitalization of the company, segment and market as a whole
RYTM - Market capitalization of the company Rhythm Pharmaceuticals
Rhythm Pharmaceuticals' market capitalization dynamics tell a focused story about the fight against rare genetic obesity diseases. The chart reflects investor expectations for the success of its drugs. Every movement on it reflects the market's assessment of the company's potential in the very narrow but vital niche of endocrinology.
RYTM - Share of the company's market capitalization Rhythm Pharmaceuticals within the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare genetic diseases associated with obesity. Its market share in its niche reflects the uniqueness of its scientific approach. The chart below shows how the market views the potential of its drugs and its leadership in this niche.
Market capitalization of the market segment - Pharma metabolism
Rhythm Pharmaceuticals develops drugs to treat rare genetic diseases that cause severe obesity. The chart below shows the market capitalization of the niche pharmaceutical sector. This represents a market where focusing on rare diseases can lead to breakthrough results.
Market capitalization of all companies included in a broad market index - GURU.Markets
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic diseases that cause obesity. The company's market cap is a bet on its ability to solve complex metabolic problems. Its stake in the global pharmaceutical industry reflects investors' belief in the potential of targeted therapies to combat obesity.
Book value capitalization of the company, segment and market as a whole
RYTM - Book value capitalization of the company Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is built on scientific capital. The company's book value, which develops drugs for rare genetic forms of obesity, consists of patents for its molecules, funds for clinical trials, and laboratory equipment. The chart below shows the accumulation of financial resources for bringing breakthrough drugs to market.
RYTM - Share of the company's book capitalization Rhythm Pharmaceuticals within the market segment - Pharma metabolism
Rhythm Pharmaceuticals, a biopharmaceutical company, relies heavily on its research laboratories. These research centers are its primary tangible asset. The S_BCap_Seg graph shows how its share of specialized infrastructure compares to that of major pharmaceutical giants.
Market segment balance sheet capitalization - Pharma metabolism
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Rhythm Pharmaceuticals, as a company developing drugs to treat rare genetic forms of obesity, looks like a "lightweight." Its value lies in its patents and scientific data, not its large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare genetic diseases associated with obesity. Its assets are not factories, but rather drug patents and clinical trial data. Against the backdrop of the entire material economy, the graph below demonstrates how targeted scientific discoveries can have enormous value.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Rhythm Pharmaceuticals
Rhythm Pharma's balance sheet consists of its cash and the patent for a drug for treating rare forms of obesity. Its market capitalization is an estimate of the drug's future commercial success. The MvsBCap_Co chart shows how many times investors value the potential of a single, breakthrough drug.
Market to book capitalization ratio in a market segment - Pharma metabolism
Rhythm Pharmaceuticals develops drugs to treat rare genetic forms of obesity. Its value lies solely in its science and patents. The chart shows that its market valuation is based entirely on expectations for the success of its drugs, far exceeding the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases that cause obesity. The company's core value lies in its scientific research and the potential for future drugs. This chart clearly demonstrates why biotech companies can achieve high valuations even with minimal tangible assets.
Debts of the company, segment and market as a whole
RYTM - Company debts Rhythm Pharmaceuticals
For Rhythm Pharmaceuticals, a biopharmaceutical company focused on rare genetic diseases associated with obesity, debt is the lifeblood of R&D. This chart shows how the company raises capital to fund the lengthy and expensive clinical trials of its drugs. In this industry, debt is an investment in science with the potential to change patients' lives.
Market segment debts - Pharma metabolism
Rhythm Pharmaceuticals is a biotech company focused on developing drugs to treat rare genetic diseases that cause obesity. The path from the lab to an approved drug is long and extremely expensive. This chart shows how the company funds its clinical trials, remaining at the forefront of the fight against rare diseases.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Rhythm Pharmaceuticals
Rhythm Pharmaceuticals develops drugs to treat rare genetic diseases that cause obesity. This chart shows the biotech company's financial position at the commercialization stage. Its debt level may reflect its strategy for funding the launch and marketing of its first approved drug, a critical milestone for its future.
Market segment debt to market segment book capitalization - Pharma metabolism
Rhythm Pharmaceuticals develops drugs to treat rare genetic diseases that cause obesity. This chart shows debt trends in their niche pharmaceutical industry. It allows one to assess how the company finances its expensive clinical trials and commercialization preparations, and how its financial model compares to other biotech startups.
Debt to book value of all companies in the market
Rhythm Pharmaceuticals, a biopharmaceutical company whose success depends on science. The chart reflects the overall market leverage. It allows us to assess how the financing of such innovative but risky companies depends on the overall risk appetite of investors. Does capital continue to flow into the industry, even when the overall market is pessimistic?
P/E of the company, segment and market as a whole
P/E - Rhythm Pharmaceuticals
For Rhythm Pharmaceuticals, a biopharmaceutical company focused on treating rare genetic obesity diseases, this chart is a measure of the company's hopes for the success of its drugs. A high or negative P/E ratio indicates that investors are evaluating the potential of its therapy, not current profits. The company's performance depends entirely on clinical trial results and regulatory approvals.
P/E of the market segment - Pharma metabolism
This is the average P/E ratio for biopharmaceutical companies. For Rhythm Pharmaceuticals, which focuses on ultra-rare diseases, this is an important, albeit conditional, benchmark. It reflects the overall level of optimism in the sector. The company's valuation will depend not on average values, but on the success of its specific drug.
P/E of the market as a whole
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic diseases that cause obesity. Its valuation, like many companies at this stage, hinges on the success of one or two drugs. Compared to this chart, which reflects average market multiples, Rhythm looks like a venture investment in breakthrough science operating outside the general market rules.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare genetic diseases that cause obesity. Its future depends on the commercial success of its first drug and the expansion of its use. This timeline reflects market expectations regarding the potential of its unique therapy and its ability to reach all patients with targeted genetic mutations.
%20P%2FE%20Rhythm%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Rhythm-Pharmaceuticals&v=1772513700518 "Chart of the company's future (projected) P/E Rhythm Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases that cause obesity. This is a very narrow and complex niche. This chart reflects expectations for the biotech sector, providing context for assessing the market's perception of the commercial potential of Rhythm's orphan disease drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772513700519 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic diseases that cause obesity. Their success depends on clinical trial results and regulatory approval. This graph of overall expectations shows investor risk appetite. During periods of market optimism, biotech companies like Rhythm find it easier to raise capital for their expensive developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513700536 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare genetic diseases that cause obesity. This timeline reflects the long journey from research to commercialization. The company's revenue will depend on the success of its lead drug, its regulatory approval, and its ability to secure insurance coverage for patients.
Profit of companies in the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic diseases that cause obesity. The company's success hinges on a single key drug. This chart reflects the high risk in biotech, where the profits can be enormous if successful, but until then, the company incurs losses on research.
Overall market profit
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic diseases that cause obesity. Its success depends solely on clinical trial results and regulatory approval. It's an example of a business whose trajectory is determined by scientific breakthroughs rather than the general economic trends reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases that cause obesity. Its revenue forecast depends on the success of its drugs and the expansion of their use. This chart reflects analyst expectations regarding the commercial potential of the company's developments and treatments for rare forms of obesity.
%20profit%20of%20the%20company%20Rhythm%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Rhythm-Pharmaceuticals&v=1772513700567 "Graph of future (projected) profit of the company Rhythm Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biotech company focused on developing drugs to treat rare genetic diseases that cause obesity. The company aims to address the root cause of the disease. This chart shows profitability forecasts for the pharmaceutical sector. It helps assess the potential of niche therapies against the backdrop of overall trends in the drug development industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772513700569 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic forms of obesity. Its success depends not on general economic cycles, but on scientific breakthroughs and regulatory approvals. However, this graph, reflecting the overall market situation, affects the availability of capital. A positive outlook facilitates attracting investment for costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513700574 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases that cause severe obesity. Its revenue depends on the success of one key drug. The chart shows how investors estimate the sales of this drug, which is a bet that the company will successfully commercialize its drug for a very specific patient group.
P/S market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for rare genetic diseases that cause obesity. This chart reflects investor expectations for companies in the sector, allowing one to assess how the market values Rhythm Pharmaceuticals' scientific potential and niche focus in the field of metabolism.
P/S of the market as a whole
Rhythm Pharmaceuticals develops drugs to treat rare genetic forms of obesity. The company targets a very narrow, but highly desirable, group of patients. This chart, showing average market valuations, clearly highlights the gap between the valuations of traditional businesses and biotech companies targeting high-potential orphan diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases associated with obesity. This chart shows how investors assess the future commercial potential of its drugs. The assessment is based on sales expectations for the currently approved drug and the success of clinical trials for new candidates.
%20P%2FS%20Rhythm%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Rhythm-Pharmaceuticals&v=1772513700626 "The graph of the company's future (projected) P/S Rhythm Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases that cause severe obesity. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in the commercial potential of its highly targeted drugs and the success of its clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772513700632 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Investor optimism about future revenue depends on breakthroughs in rare disease treatments. Rhythm Pharmaceuticals is focused on developing treatments for genetically determined obesity. Their success in research and commercialization could not only change the lives of patients but also demonstrate how biotechnology opens new markets, stimulating growth across the industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513700636 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic forms of obesity. Its revenue is almost entirely dependent on sales of a single drug, Imcivree. This chart clearly illustrates the commercial trajectory of this highly specialized drug, reflecting its adoption by doctors and patients in a very niche market.
Sales of companies in the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases that cause severe obesity. This chart shows total revenue in the metabolism-focused pharmaceutical segment. It illustrates the potential market size for highly targeted drugs, where Rhythm aims to become a leader.
Overall market sales
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases that cause obesity. Its success depends on the development and commercialization of its drugs. Demand for such highly specialized drugs depends less on the overall economics shown in this chart and more on insurance coverage and clinical need.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic diseases that cause obesity. Its success depends on sales of its only approved drug. The chart shows analyst revenue forecasts, reflecting their expectations for new patient acquisition and expanded use of the drug.
%20sales%20of%20the%20company%20Rhythm%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Rhythm-Pharmaceuticals&v=1772513700652 "Schedule of future (projected) sales of the company Rhythm Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biotech company specializing in the treatment of rare genetic diseases associated with obesity. Its success depends on the approval and commercialization of its drugs. This chart displays projected sales for the entire metabolism-related pharmaceutical segment, demonstrating analysts' overall growth expectations for this specific area of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772513700657 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases associated with obesity. Its success depends on the results of clinical trials and the commercialization of a single drug. This overall economic activity has an indirect impact, primarily through its impact on healthcare and insurance budgets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513700661 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is developing drugs to treat rare genetic diseases that cause obesity. This chart reflects the biotech company's complex journey. It shows how successfully Rhythm converts revenue from its first approved drugs into net profit, covering its enormous R&D costs.
Market segment marginality - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases associated with obesity. For a niche biotech, its operating structure reflects its stage of development. This chart shows its current research and commercialization expenditures relative to other players, which is an indicator of its path to potential profitability.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases associated with obesity. While in the commercialization phase of its first drug, the company is rapidly growing. This chart shows how it is expanding its commercial team to work with physicians and its scientific staff for further research.
Share of the company's employees Rhythm Pharmaceuticals within the market segment - Pharma metabolism
Rhythm Pharmaceuticals develops treatments for rare genetic diseases that cause obesity. This chart shows the concentration of unique scientists and clinicians working in this niche area. This share of such specialists reflects its leadership in finding solutions for patients with severe metabolic disorders.
Number of employees in the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic diseases that cause obesity. This chart shows overall employment in the pharmaceutical industry. It illustrates the overall talent landscape in which Rhythm, as a highly specialized company, competes for the best scientists and clinicians to advance its unique drugs.
Number of employees in the market as a whole
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases that cause obesity. This timeline reflects the company's journey from research to commercialization. Staff growth, particularly in the sales and marketing departments, follows the approval of its drug, which requires building a team to promote it to physicians.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals is a biotech company focused on rare genetic obesity diseases. This chart shows that its market capitalization is based solely on the scientific potential of its developments. The market values intellectual property, resulting in a very high cost per employee.
%20of%20the%20company%20Rhythm%20Pharmaceuticals%20(RYTM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Rhythm-Pharmaceuticals-RYTM&v=1772513700853 "Chart of market capitalization per employee (in thousands of dollars) of the company Rhythm Pharmaceuticals (RYTM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic forms of obesity. It's a speculative, R&D-intensive IP business. Their value lies in their scientific developments. This metric, compared to the industry average, reflects how highly the market values their patents and the potential per scientist.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772513700865 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Rhythm Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic diseases that cause obesity. Its valuation is entirely dependent on the success of clinical trials. The high valuation per employee reflects investors' bet that a small team of scientists will be able to bring a unique and in-demand drug to market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513700921 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals is a biotech company specializing in rare genetic diseases that cause obesity. Their focus is on developing and commercializing niche drugs. This chart shows how successfully their small, highly specialized staff (scientists, doctors, and salespeople) generates revenue from the sale of these expensive drugs.
%20Chart%20Rhythm%20Pharmaceuticals%20(RYTM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Rhythm-Pharmaceuticals-RYTM&v=1772513700943 "Company Profit Per Employee (in thousands of dollars) Chart Rhythm Pharmaceuticals (RYTM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Rhythm Pharma is a biopharmaceutical company focused on "rare" "genetic" forms of "obesity." This chart shows the benchmark for "Pharma Metabolism." In this sector (orphan and rare diseases), labor profitability is exorbitant. Monopolistic companies in their niche set very high drug prices.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772513700951 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focused on developing treatments for rare genetic diseases that cause obesity. Their lead drug targets the MC4R pathway. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513700967 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Rhythm Pharmaceuticals (RYTM)
For Rhythm Pharmaceuticals, a biopharmaceutical company focused on rare genetic diseases of obesity, this chart reflects the commercialization of its unique drug. High revenue per employee indicates a high price and value for a small group of patients.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Rhythm-Pharmaceuticals-RYTM&v=1772513700999 "Sales chart per company employee Rhythm Pharmaceuticals (RYTM)")
Sales per employee in the market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company specializing in rare genetic diseases that cause obesity. This is a highly specialized R&D company. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive Rhythm's team is in developing and commercializing its orphan drugs compared to other biotech companies.
Sales per employee for the market as a whole
Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focused on treating rare genetic diseases that cause obesity. For a pharmaceutical company with an approved drug, this metric reflects commercial success. The growth in revenue per employee demonstrates how effectively their relatively small team can generate revenue from their highly specialized drug.
Short shares by company, segment and market as a whole
Shares shorted by company Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic forms of obesity. While its approach is unique, it faces the emergence of a new class of drugs (GLP-1). This chart reflects investor bets that the widespread success of drugs like Ozempic will make Rhythm's niche product less relevant, even though they treat different causes.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Rhythm-Pharmaceuticals-RYTM&v=1772513701253 "Short Shares Chart for the Company Rhythm Pharmaceuticals (RYTM)")
Shares shorted by market segment - Pharma metabolism
Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company specializing in the treatment of rare genetic diseases that cause obesity. This chart shows the overall short position in the biotech sector. It reflects investor skepticism regarding the commercial potential of drugs for very niche (orphan) markets.
Shares shorted by the overall market
Rhythm Pharmaceuticals is a biotech company focused on treating rare genetic forms of obesity. Such companies are often unprofitable and dependent on external funding. The rise of Short_All signals market fear and risk aversion. This pessimism prevents speculative biotechs from raising the capital needed for research, regardless of their scientific potential.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Rhythm Pharmaceuticals (RYTM)
Rhythm is a biotech focused on treating rare genetic forms of obesity. **This chart** measures the response to binary events. Successful Phase 3 data for their drug or an expanded indication could trigger explosive growth and euphoria (above 70). A failed trial would send **This chart** into panic mode (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Rhythm-Pharmaceuticals-RYTM&v=1772513701502 "RSI 14 indicator chart for the company's stock Rhythm Pharmaceuticals (RYTM)")
RSI 14 Market Segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases that cause severe obesity. This is a very narrow and specific niche in metabolic medicine. This chart shows the overall sentiment in the metabolism biotech sector. It helps assess whether RYTM's performance represents a unique success story (or failure) or part of a broader biotech trend.
RSI 14 for the overall market
Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focused on rare genetic diseases that cause obesity. It's a venture capital story. This indicator of market "risk appetite" is vital for RYTM. During periods of euphoria (high values), investors are willing to fund unprofitable biotechs with promising drugs. During moments of panic (low values), capital for R&D dries up.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RYTM (Rhythm Pharmaceuticals)
Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focused on treating rare genetic diseases that cause obesity. Their drug, Imcivree, targets specific gene mutations. This chart shows the average analyst forecast. It reflects their assessment of the drug's commercial potential and the progress of clinical trials to expand its use.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RYTM-Rhythm-Pharmaceuticals&v=1772513701734 "A chart showing analyst consensus forecasts for the expected stock price. RYTM (Rhythm Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price RYTM (Rhythm Pharmaceuticals)
Rhythm Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic forms of obesity. This chart shows the difference between the consensus estimate and the price. It reflects whether analysts believe in the commercial potential of its ultra-niche drugs and its R&D pipeline, seeing potential in them.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RYTM-Rhythm-Pharmaceuticals&v=1772513701767 "A chart showing the difference between the consensus forecast and the actual stock price. RYTM (Rhythm Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare genetic diseases that cause obesity. This is a highly specialized market. This chart shows analysts' overall expectations for the metabolism sector. It reflects whether experts believe in the potential of this niche segment of obesity treatment.
Analysts' consensus forecast for the overall market share price
Rhythm Pharmaceuticals is a niche biotech focused on treating rare genetic obesity diseases. It's a risky R&D play. This chart of overall market sentiment is important. Optimism = the market is willing to fund unprofitable biotech companies with great potential. Pessimism = risk aversion, and R&D capital dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biotech company focused on rare genetic diseases that cause obesity. Their drug, Imcivree, targets specific gene mutations. This chart is a pure biotech bet. It reflects not the overall obesity market, but their ability to identify patients and commercialize their drug for ultra-rare diseases.
AKIMA Market Segment Index - Pharma metabolism
Rhythm Pharmaceuticals is a highly specialized biotech company focused on developing drugs (Imcivree) for the treatment of rare genetic forms of obesity. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark provides insight into how Rhythm's niche (rare obesity) R&D strategy differentiates it from the average pharmaceutical company.
The AKIM Index for the overall market
Rhythm Pharma is a biotech company focused on treating rare genetic forms of obesity. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends that influence risk appetite.
